期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 6, 页码 1441-1449出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2021.1872068
关键词
Plerixafor; G-CSF; MDS; azacitidine
资金
- Cancer Center Support Grant from the National Cancer Institute at the National Institutes of Health [P30 CA91842]
- Sanofi
- National Institutes of Health [R01 CA152329, R21 CA141523, R35 1R35CA210084, 5K12HL08710703]
- Washington University Institute of Clinical and Translational Sciences from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) [UL1 TR000448]
- CALGB/Alliance for Clinical Trials in Oncology Foundation
The interaction between the bone marrow microenvironment and MDS tumor clones play an important role in disease pathogenesis and response to treatment. The combination therapy of plerixafor, G-CSF, and azacitidine shows promising response rates in MDS patients, with evidence of mobilization correlating with a higher overall response rate.
Interactions between the bone marrow microenvironment and MDS tumor clones play a role in pathogenesis and response to treatment. We hypothesized G-CSF and plerixafor may enhance sensitivity to azacitidine in MDS. Twenty-eight patients with MDS were treated with plerixafor, G-CSF and azacitidine with a standard 3 + 3 design. Subjects received G-CSF 10 mcg/kg D1-D8, plerixafor D4-D8, and azacitidine 75 mg/m(2) D4-D8, but the trial was amended to reduce G-CSF dose to 5 mcg/kg for 5 days after 2 patients had significant leukocytosis. Plerixafor was dose escalated to 560 mcg/kg/day without dose limiting toxicity. Two complete responses and 6 marrow responses were seen for an overall response rate (ORR) of 36% in evaluable patients, and ORR of 53% in patients receiving the triplet. Evidence of mobilization correlated with a higher ORR, 60% vs. 17%. Plerixafor, G-CSF and azacitidine appears tolerable when given over 5 days and has encouraging response rates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据